Key Highlights
- Net loss was USD 107.4 million, or USD 9.36 per share.
- A USD 102.0 million Impairment of in-process Research and Development was recorded.
- Research and development expense rose to USD 3.5 million from USD 3.2 million.
- Cash was approximately USD 4.6 million at September 30, 2026.
An Impairment Dominates the Quarter
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) reported a third-quarter net loss of USD 107,382,178, or USD 9.36 per share, versus USD 4,856,051, or USD 5.82. Total operating expenses were USD 109,685,884 versus USD 4,561,200, driven by a USD 102,000,000 impairment of in-process research and development.
Research and development expense was USD 3,548,129 versus USD 3,161,064, and general and administrative expense rose to USD 3,757,755 from USD 1,400,136. SEPA financing issuance costs were USD 380,000.
The nine-month impairment is the same USD 102,000,000 charge, and the nine-month operating loss was USD 134,230,418 versus USD 11,953,514 a year earlier.
Other Income Items and Nine-Month Results
The quarter included a USD 241,003 change in Fair Value of Warrant liabilities versus a loss of USD 279,161, a USD 1,062,000 change in fair value of contingent consideration, a USD 602,387 change in fair value of convertible notes payable and grant income of USD 63,946 versus USD 22,174.
For the nine months, net loss was USD 131,917,377 versus USD 21,217,966. After accrual of paid-in-kind dividends of USD 1,840,240 on Series A non-voting convertible preferred stock, net loss attributable to common stockholders was USD 133,757,617, or USD 29.85 per share versus USD 34.49. Research and development was USD 12,348,942 versus USD 7,946,573, and total operating expenses were USD 134,230,418 versus USD 11,953,514.
Cash flow adjustments in the filing include a non-cash SEPA commitment fee of USD 280,000 settled in common stock, share-based compensation of USD 315,314 and a loss on litigation settlement of USD 291,670.
Grant income for the nine months was USD 225,097 versus USD 523,704, and the change in fair value of warrant liabilities was a gain of USD 344,876 versus a loss of USD 9,675,797 a year earlier. The Cash Flow statement also lists a USD 961,000 contingent consideration adjustment and a USD 592,853 convertible notes adjustment.
Pipeline and Balance Sheet
The company describes itself as an "immuno-oncology and targeted cancer therapy company" focused on advanced malignancy. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, and it obtained a second principal candidate, seviprotimut-L, through its Acquisition of Polynoma.
The filing says a Phase I/II trial of TTX-MC138, begun in September 2024, substantially met its primary safety endpoint by the end of 2025. Total liabilities were USD 12,608,480 versus USD 10,518,687 at December 31, 2025, and net cash used in Operating Activities for the nine months was USD 18,042,782 versus USD 11,374,219. The company had cash of approximately USD 4.6 million.
Items to Follow
Reference points include the carrying value of acquired programs after the impairment, general and administrative costs, the SEPA financing arrangement and the cash balance against operating cash use.
The company reports its results in whole dollars and describes itself as a smaller reporting company under the filing's definition.






Please wait processing your request...